Guggenheim lowered its price target to $60 from $68
The shares of Adaptive Biotechnologies Corp (NASDAQ:ADPT) are sinking even lower today, following a price-target cut to $60 from $68 from Guggenheim. The stock is set to extend its four-day losing streak today, which has put it at a roughly 25% month-to-date deficit by the close on Friday. At last check, ADPT is down 2.7% at $41.08.
Drilling down, it looks like the 10-day moving average has put some pressure on ADPT of late, while the $65 mark has also been a point of contention since late last year. While the stock briefly toppled both areas to hit an all-time high of $71.25 on Jan. 19, both of these levels act as potential overhead pressure on the charts.
Despite this recent tumble, most members of the brokerage bunch are optimistic on the stock. Of the seven covering ADPT, just one considers it a "hold," compared to six "strong sell" ratings. Plus, the 12-month consensus price target of $64.80 is a 53.5% premium to Friday's close.
While calls are still outnumbering puts on an overall basis, it looks like these traders have been more bearish than usual. This is per ADPT's 50-day put/call volume ratio at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which stands higher than 80% of readings from the past 12 months and implies puts have rarely been more popular of late.